Bristol-Myers Squibb (BMY) Tops Q3 EPS by 6c

Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.06 better than the analyst estimate of $1.94. Revenue for the quarter came in at $11.62 billion versus the consensus estimate of $11.64 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.40-$7.55, versus the consensus of $7.47.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c